Related Experiment Video
Updated: May 16, 2026
08:15
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Neurobiological Insights into Depression: The STAT3 Signaling Pathway as a Therapeutic Target
Chen Dong1, Xiaoke Tian1, Xiaoguang Zhang2
1Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, 475004, China.
Current Neuropharmacology
|May 15, 2026
Summary
Signal Transducer and Activator of Transcription 3 (STAT3) plays a dual role in depression. Targeting STAT3 may offer new therapeutic strategies for depression by modulating neuroinflammation and neurogenesis.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Signal Transducer and Activator of Transcription 3 (STAT3) is a key regulator of cellular processes.
- STAT3 has dual roles in the nervous system, promoting neuroprotection when physiological and exacerbating damage when overactivated.
- Emerging evidence links the STAT3 signaling pathway to the development of depression.
Purpose of the Study:
- To review the mechanisms of the STAT3 signaling pathway in depression.
- To analyze STAT3's role in neuroinflammation, neurogenesis, apoptosis, synaptic function, and hormone regulation in depression.
- To evaluate STAT3 as a potential therapeutic target for depression.
Main Methods:
- Review of existing literature on STAT3 signaling and depression.
- Analysis of the JAK/STAT pathway's role in neuronal survival and function.
- Examination of STAT3's multi-target regulatory potential.
Main Results:
- STAT3 activation is implicated in the pathophysiology of depression.
- Overactivated STAT3 contributes to neuroinflammation, apoptosis, and synaptic dysfunction in depression.
- STAT3 influences neurogenesis and hormone regulation relevant to depression.
Conclusions:
- STAT3 is a critical regulator in depression.
- Targeting STAT3 offers potential for novel depression treatments.
- Combining STAT3-targeted therapies with antidepressants may improve outcomes.
Related Concept Videos
01:18Depression: Overview
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
01:27Depressive Disorders: Etiology
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
02:26NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...